Archives
AAL-993 and the Translational Logic of Angiogenesis
2026-09-24
A mechanistic and strategic look at AAL-993 as a VEGF receptor inhibitor for angiogenesis research, including how to interpret its preclinical profile alongside emerging glioma signaling research—without conflating distinct mechanisms or overstating translational evidence.
GST Drives Thrips Resistance Through Antioxidant Defense
2026-09-23
The study identifies MuGSTs1 and GST activity as contributors to lambda-cyhalothrin resistance in Megalurothrips usitatus, linking pesticide exposure to oxidative stress and antioxidant defense. Inhibiting GST reduced antioxidant capacity and increased insecticide sensitivity, offering a mechanistic basis for resistance research while leaving field-level control strategies to be tested.
Naringin, VEGFC, and Hepatic Fibrosis
2026-09-23
The reference study identifies a hepatocyte-derived VEGFC–VEGFR-3–CCL2/CCR2 axis that promotes Ly6Chigh monocyte recruitment and sustains inflammatory macrophage states during diet-induced hepatic fibrosis. By combining pharmacological inhibition, hepatocyte-specific Vegfc deletion, patient data, and hepatocyte–macrophage co-culture models, the work explains how naringin limits fibrosis and establishes VEGFR-3 signaling as a mechanistically testable target.
Tariquidar: A Mechanical-Context Assay Guide
2026-09-22
Tariquidar and XR9576 are powerful tools for studying P-glycoprotein-mediated drug efflux. This guide shows how tumor viscosity and mechanotransduction can alter ABC transporter inhibition results and improve assay interpretation.
PD0325901: MEK Inhibitor Workflow for Cancer Research
2026-09-22
PD0325901 combines pathway-level MEK inhibition with practical readouts for P-ERK suppression, cell-cycle control, and apoptosis. Its use as an orthogonal perturbation also creates a hypothesis-driven bridge between oncogenic signaling and APEX2-dependent TERT regulation in stem-cell and melanoma models.
GDC-0994: From ERK Signaling to Causal Evidence
2026-09-21
Explore how GDC-0994, a selective ERK1/2 inhibitor, can connect pathway engagement with interpretable cancer and cholestatic injury phenotypes. This article emphasizes causal assay design, cross-model limitations, and evidence-based interpretation rather than repeating a conventional workflow.
Fluconazole: A Mechanistic Lens on Candida Resistance
2026-09-21
Fluconazole is more than an antifungal benchmark: it can expose how ergosterol disruption interacts with Candida albicans biofilm biology, PP2A signaling, autophagy, and drug resistance. This guide translates recent mechanistic findings into more informative assay design and interpretation.
Chuanxiong Cortex–Pith Mechanisms in CHD
2026-09-20
The reference study distinguishes the volatile chemistry and predicted pharmacology of Chuanxiong cortex and pith using SPME-GC×GC-MS, network pharmacology, pathway analysis, and molecular docking. Its identification of Fenipentol among the principal cortex-associated compounds provides a rational basis for prioritizing candidates, while also showing why computational results require biochemical and disease-model validation.
Benzyl-activated Streptavidin Magnetic Beads
2026-09-19
Benzyl-activated Streptavidin Magnetic Beads (SKU: K1301) provide magnetic capture of biotinylated proteins, nucleic acids, peptides, antibodies, sugars, and other targets from complex samples. They are appropriate for streptavidin–biotin workflows, but not for non-biotinylated targets, direct covalent immobilization, or unvalidated buffer conditions.
FLT3–TAZ Signaling in Drug-Resistant BP-CML
2026-09-18
Shin et al. reposition FLT3 as a prognostic and therapeutic determinant of blast-phase CML, showing that FLT3-JAK-STAT3-TAZ-TEAD-CD36 signaling promotes resistance to BCR::ABL1 tyrosine kinase inhibitors. Their patient, cell, multi-omics, and xenograft evidence supports combining FLT3-directed strategies with BCR::ABL1 therapy while highlighting the need to validate FLT3 expression and localization in individual samples.
Anlotinib: Selective VEGFR2 Inhibition in Cancer
2026-09-18
The reference study established anlotinib as a highly potent, orally active VEGFR2 inhibitor that suppresses endothelial signaling and tumor angiogenesis in preclinical models. Its key contribution was linking ATP-pocket binding and kinase selectivity to endothelial functional assays, vascular remodeling, and stronger antitumor activity than sunitinib in several mouse models.
Dorsomorphin Workflows for AMPK and BMP Research
2026-09-17
Dorsomorphin, also called Compound C, enables reversible interrogation of AMPK-dependent metabolism, autophagy, BMP signaling, and iron homeostasis. This practical guide combines pathway-specific workflows with time-resolved assay design and troubleshooting for more interpretable cell, embryo, and translational studies.
AAL-993 VEGF Receptor Inhibitor Workflow
2026-09-17
AAL-993 supports a mechanism-first workflow that separates VEGFR-dependent endothelial effects from direct tumor-cell responses. This guide combines kinase profiling, angiogenesis assays, migration readouts, and glioma-inspired pathway analysis for more interpretable tumor angiogenesis research.
GPR30, Spinal CCK+ Neurons, and Neuropathic Pain
2026-09-16
A recent eLife study identifies GPR30 in spinal cholecystokinin-positive neurons as a key contributor to nerve-injury-induced pain. By combining cell-type analysis, synaptic physiology, projection mapping, and chemogenetic circuit manipulation, the work connects spinal estrogen-receptor signaling with AMPA-mediated sensitization and primary sensory cortex input.
Remdesivir (GS-5734): From Assay to Evidence
2026-09-16
Remdesivir and GS-5734 are examined through an evidence-to-assay framework spanning coronavirus antiviral research, Ebola models, and emerging RNA viruses. Learn how to interpret potency, treatment timing, formulation, and cross-virus limitations without overextending the data.
605 records 7/41 page Previous Next First page 上5页 678910 下5页 Last page